EtiologyRecent advances in surgical technique and perioperative management, as well as more careful patient selection and better understanding of liver anatomy and physiology, have significantly improved mortality rates to less than 3-5 % after liver and pancreas surgery. However, the overall morbidity rate after hepatic resection remains high, ranging from 15 to 45 %, and up to 80 % in prospectively collected series evaluating pancreaticoduodenectomy (PD) [1][2][3][4][5][6][7][8][9][10][11][12]. The incidence of postoperative hepatic infection has been reported to vary between 2.6 and 8.6 % in more recent large studies [1][2][3][4][5][6][7][8][9][10][11][12]. In pancreas surgery, the risk occurs following PD but not distal pancreatectomy, which is likely due to the most wellrecognized contributing factor-the presence of a biliary-enteric anastomosis [8].The negative impact of postoperative complications on long-term oncological outcome has been reported after partial hepatectomy for colorectal metastases and hepatocellular carcinoma with postoperative sepsis being an independent predictor influencing disease free and overall survival [3,4,[13][14][15]. The mechanism behind which postoperative sepsis negatively affects long-term outcomes in oncologic surgery is not completely understood, but has been linked to negative effects of the systemic inflammatory response on the immune system. In addition to the adverse effect of postoperative infectious complications on long-term outcomes after liver and pancreas surgery, the morbidity of infectious complications also results in increased hospital stay, resource utilization with subsequent higher costs of inpatient stay, and mortality. Therefore, early recognition and aggressive treatment of infectious complications are of pivotal importance to reduce postoperative complications and improve oncologic outcomes.Perioperative blood loss and blood transfusion have been associated with systemic side effects and negative impacts on postoperative outcome, with blood loss remaining one of the main predictors of morbidity and mortality after liver and pancreas resection [14][15][16][17][18][19]. Blood product transfusion has been assumed to have a deleterious effect on the immune system by suppressive effects on host immunity via a reduction in natural killer cell function, decreased cytotoxic T-cell function, increased numbers of suppressor T cells, and decreased function of macrophages and monocytes. Some of these effects may be mitigated by the use of leukocyte depleted allogenic blood